 |
 |

Doxycycline in the Prevention of Hepatic DysfunctionAn Evaluation of Its Use Following Jejunoileal Bypass in Humans
Richard L. Yost, PharmD;
Margaret C. Duerson, BSN;
Wayne L. Russell, PharmD;
J. Patrick O'Leary, MD
Arch Surg. 1979;114(8):931-934.
Abstract
A prospective randomized study was carried out to evaluate doxycycline hyclate in the prevention of hepatic dysfunction following jejunoileal bypass for morbid obesity. Forty-five patients were entered into the study and were observed for a year or more. Patients received either 100 mg of doxycycline hyclate twice daily on postoperative days 5 through 10 and then 100 mg daily for six weeks, or no drug. At six weeks, 12 weeks, and 12 months after the operation, biochemical levels were measured. After one year all patients had a liver biopsy. Doxycycline, in the regimen, was not demonstrated to be of value in the prevention of hepatic dysfunction in these patients. A lack of correlation was demonstrated between the biochemical definition of hepatic dysfunction and liver histopathology.
(Arch Surg 114:931-934, 1979)
Author Affiliations
From the College of Pharmacy (Dr Yost) and the College of Medicine (Ms Duerson and Dr O'Leary), University of Florida, Gainesville, and the St Louis College of Pharmacy, St Louis (Dr Russell).
Footnotes
Accepted for publication Feb 28, 1979.
Reprint requests to College of Pharmacy, Box J-4, J. Hillis Miller Health Center, Gainesville, FL 32610 (Dr Yost).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Is bacterial ash the flash that ignites NASH?
FARRELL
Gut 2001;48:148-149.
FULL TEXT
Jejunoileal Bypass: Pass It By
Clayman and O'Reilly
JAMA 1981;246:988-988.
ABSTRACT
|